Mozes kriebel schreef op 1 maart 2020 16:50:
Ook onderstaande zal nog moeten blijken halverwege 2020. In ieder geval wordt het een interessant jaar.
Outlook for 2020
In 2020, management will continue to focus on increasing gross margins and EBITDA profitability
while carefully managing working capital to restore stock levels and deliver sustainable revenue
growth. The planned overhead savings will not only improve profitability but extend the Company’s
cash runway and enable further investment in rebuilding the supply chain, which is expected to be
completed by the middle of 2020.
Further cash could be generated in the first half of the year from the sale of the residual NOVAprep®
assets, which would provide further working capital. Negotiations are currently underway with various
parties to sell the remaining instruments and also some of the residual IP following the successful sale
of certain assets to Algimed Trade Ltd in December 2019 for €0.4m plus royalties.